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Abstract
The imprinted oncofetal long non-coding RNA (lncRNA) H19 is expressed in the embryo, down-regulated at birth
and then reappears in tumors. Its role in tumor initiation and progression has long been a subject of controversy,
although accumulating data suggest that H19 is one of the major genes in cancer. It is actively involved in all
stages of tumorigenesis and is expressed in almost every human cancer. In this review we delineate the various
functions of H19 during the different stages in the complex process of tumor progression. H19 up-regulation allows
cells to enter a “selfish” survival mode in response to stress conditions, such as destabilization of the genome and
hypoxia, by accelerating their proliferation rate and increasing overall cellular resistance to stress. This response is
tightly correlated with nullification, dysfunction or significant down-regulation of the master tumor suppressor gene
P53. The growing evidence of H19’s involvement in both proliferation and differentiation processes, together with
its involvement in epithelial to mesenchymal transition (EMT) and also mesenchymal to epithelial transition (MET),
has led us to conclude that some of the recent disputes and discrepancies arising from current research findings
can be resolved from a viewpoint supporting the oncogenic properties of H19. According to a holistic approach,
the versatile, seemingly contradictory functions of H19 are essential to, and differentially harnessed by, the tumor
cell depending on its context within the process of tumor progression.
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Background
Tumorigenesis is a multistep process that involves both
the neoplastic tissue and its surroundings. In order to
survive and flourish, cancer cells acquire a unique genetic
background, proliferate rapidly, evade growth suppressors,
cell death pathways and immune system attacks, and resist
multiple drug treatments. Cancer cells are experts in man-
aging hypoxia and stress conditions by recruiting blood
supply to the neoplastic tissue, adjusting metabolically and
adopting the plasticity that should enable epithelial to
mesenchymal transition (EMT), metastasis and coloniza-
tion at secondary sites [1]. In many aspects, a cancer cell
resembles an embryonic cell: they share extraordinary
plasticity, proliferation, motility and invasiveness capabil-
ities, as well as the ability to make metabolic adjustments
and other attributes, all orchestrated by common molecu-
lar pathways and epigenetic patterns [2].
One of the pivotal players in both embryonic develop-
ment and tumorigenesis is the oncofetal lncRNA gene
H19. H19, a maternally expressed and paternally im-
printed 2.7 kb gene, resides close to the telomeric region
of chromosome 11p15.5 and is reciprocally imprinted and
regulated with its neighboring gene IGF2. Its genomic
locus is rich in transcript coding sequences residing on
both strands, as we have discussed elsewhere [3]. How-
ever, one of the most important transcripts in the H19
locus is miR-675, a highly conserved micro-RNA that
resides within exon-1 of the H19 gene.
Recent studies have highlighted the important roles of
H19 during the complex process of tumorigenesis, start-
ing from the early stages that involve translational deregu-
lation and genomic instability, through proliferation
imbalance and stress management to metastasis. In this
article we review the role of H19 in the tumorigenic
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multistep process and show how H19 touches almost
every aspect of tumorigenesis. We also describe how H19
functions as an initial tumorigenic output component in
the mammalian feedback system responding to various
stress conditions. We suggest a general unifying theory
that may answer some of the disputes and discrepancies
that have arisen in regard to the fundamental characteris-
tics of the H19 gene.
H19 mechanism of action
H19 has a highly conserved secondary structure. This
evolutionary conservation suggests that H19's function
is structure-dependent [4]. H19's function can be dis-
sected into two major functions; a reservoir of miR-675
that suppresses its targets [5, 6], and a modulator of
micro-RNAs or proteins via their binding.
MiR-675 targets a myriad of transcripts in a cellular-
context-dependent manner [5]. For example, miR-675 dir-
ectly downregulates Igf1r [5], Smad1, Smad5, and Cdc6
[7],Cadherin-11 [8], Cadherin-13 [9], Rb [10], Runx1 [11],
Nodal Modulator 1 [12], TGFBI [13] CALN1 [14], and
MITF [15]. Indirect targets of miR-675 were also reported
and some of them will be mentioned below.
Increasing data suggests a role for the full length H19
transcript as a decoy for micro-RNAs that modulates
their availability and suppresses their activity [16–18].
H19 was also found to interact with transcription-
repressors and guide them to specific loci; H19 binds
the methyl-CpG–binding domain protein 1 MBD1 and
recruits it to some of its targets (including H19’s recipro-
cally imprinted gene Igf2), thus enables the maintaining
of repressive H3K9me3 histone marks in their loci [19].
H19 also interacts with enhancer of zeste homolog 2
(EZH2), a histone H3 Lys 27 (H3K27) methyltransferase,
that represses gene expression as part of the Polycomb-
Repressive Complex 2 (PRC2) [20]. In fibroblasts, H19
RNA itself is intracellularly sublocalized in lamellipodia
and perinuclear regions through the binding of its 3’ to
PTB (polypyrimidine tract-binding protein) and to 4
molecules of IGF2 mRNA-binding protein 1 (IGF2BP1)
[21]. In gastric cancer, H19 was also found to bind P53
and partially inactivate it [22], and to bind ISM1
(Isthmin 1) in what seems to support a higher expression
of this protein [14]. H19 was also found to bind the RNA
binding protein K homology-type splicing regulatory pro-
tein (KSRP) [23]. This interaction supports KSRP targeting
of unstable mRNAs, such as Myogenin, that leads to their
subsequent decay. By that, H19 maintains an undifferenti-
ated cellular state.
H19 and P53: A tight relationship
Since p53 is the major tumor suppressor gene in cancer, it
is not surprising that H19 and p53 are mutually counter-
regulated. Not only does P53 repress the promoter activity
of the H19 gene [24, 25], it also epigenetically suppresses
H19 expression in vivo by inducing DNA demethylation
of the imprinting control region (ICR) upstream to the
H19 gene [26]. We also have shown that hypoxia triggers
H19 expression in p53 deficient cell lines [27], as will be
later discussed. Moreover, it was recently found in bladder
cancer cells that H19 derived miR-675 has a major role in
inhibiting p53 and p53-dependent protein expression [28].
On the other hand, in gastric cancer cells H19 RNA was
shown to interact with P53 protein, causing its partial in-
activation [22], in what seems to be a negative feedback
loop. As will be discussed below, this P53-H19 inter-
play is fundamental to understanding the role of H19 in
tumorigenesis.
H19 and genomic instability
Chromosomal instability (CIS) and overall genomic
instability (including chromosomal aberrations and other
mutations) were recognized as early as the beginning of
the 20th century by Bovery as one of the most basic
tumor-enabling attributes of cancer (reviewed in [29,
30]). In the somatic cell, chromosomal stability and a
balanced number of paired chromosomes are essential
for appropriate gene expression and chromosome segre-
gation during the normal cell cycle. Thus, the cell cycle
process is kept under strict molecular surveillance to
prevent unbalanced segregation, replication of damaged
DNA and incomplete replication [30]. However, when
vital caretaker genes (“genome guardians”) and gate-
keeper genes (“proliferation buffers”) such as p53, Rb
and others are dysfunctional, as in tumor initiation, the
way is wide open for the accumulation of mutations and
chromosomal missegregations [31]. These not only make
the cell susceptible to future damage but also burden it
with immediate metabolic stress, forcing the cell to ac-
commodate to the alterations in its genomic content.
On the other hand, it is these very genomic alterations
that may confer the cell the genetic diversity necessary
to manage stress [32, 33]. This possible advantage may
provide an explanation for the various effects of hypoxic
stress on genetic instability [34]; for the common poly-
ploidy found in liver cells, which are under continuous
oxidative and cytotoxic stress or following hepatectomy;
and for other mechanical and metabolic stress conditions
in which polyploidy is commonly reported (reviewed in
[35]). As a comprehensive theory to explain the high rate
of aneuploidy in tumors [36, 37], it was suggested that
polyploidy is an intermediate, but sometimes unstable
stage, that tends to attenuate proliferation (reviewed in
[38, 39]) but also serves as a gateway karyotype to aneu-
ploidy [30, 35, 40]. Moreover, the low proliferation rate of
polyploid cells confers on them resistance to drugs that
target actively cycling cells. Polyploid cells, due to their
multiple but diverse chromosomes, have an inherent
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genetic system that buffers against deleterious mutations.
Polyploidy cells also adopt attributes of stem cells, namely
plasticity and metabolic reprogramming (reviewed in
[40]), which make them an excellent starting point for
more aggressive tumor descendants.
Recent studies by Zipori and colleagues [41, 42] have
shown that H19 regulates polyploidy and that H19
expression is positively correlated with polyploidy sup-
pression and tumorigenesis. These studies revealed that
polyploid bone marrow mesenchymal stromal cells (BM
MSC) have far less tumorigenic potential than diploid
ones, have higher resistance to UV irradiation, and differ
from diploid cells by their significantly lower H19 ex-
pression levels. This correlation between H19 expression
and ploidy level was further demonstrated in mouse liver
cells, which are diploid in the suckling mouse but drifted
toward polyploidy with age progression while signifi-
cantly decreasing their H19 expression. Moreover, H19
knock-down in diploid MSC caused them to drift toward
polyploidy and reduced their tumorigenic attributes and
UV sensitivity. H19 knock-down also improved the effi-
ciency of artificial tetraploidization in these cells. On the
other hand, artificial tetraploidization itself reduced H19
levels, suggesting a negative feedback loop mechanism
in which H19 represses polyploidy, which in turn re-
presses H19 expression to maintain a polyploid state.
However, comparison of BM MSC with adipose MSC
revealed lower H19 expression in the latter cells, accom-
panied by diploid nature and a higher P53 level [42]. As
both of the cell types had WT p53 gene, the differences
were probably due to epigenetic regulation of p53 [42].
Indeed, when challenged with UV radiation, oxidative
stress and chemotherapy, BM MSC responded by elevated
expression of P53’s target genes, although the response
was greater than in adipose MSC due to the relative low
basal activity of p53 in BM MSC. This study provides fur-
ther support for P53-H19 counter-regulation. Surprisingly,
H19 levels were also reported to increase in tetraploid
MSC in response to UV radiation [41].
According to a model suggested by Zipori and col-
leagues based on their findings, P53, a pivotal determin-
ant of CIS and a well-known genome keeper, interplays
with H19 in cellular homeostasis. Upon downregulation
of p53, cells are subjected to stress and can handle this
by initiating either a selfish “cancerous plan” which is
characterized by upregulated H19, or a “polyploidy plan”
that enables the stressed cell to attenuate proliferation
and acquire a genetic buffer from its high genomic con-
tent (Fig. 1). In the latter scenario, the cells enter a risky,
temporarily stable state, which commonly leads later to
aneuploidy as mentioned above. Lower levels of P53 to-
gether with the relatively unstable state of the polyploidy
cell population may encourage a tumorigenic process in
this population. The fact that H19 levels are increased in
tetraploid MSC following UV radiation may support
their pro-tumorigenic state. Aneuploid cells arising from
the process described above may thus re-express H19 at
even a higher magnitude than that of their ancestor
diploid population in order to further support tumori-
genic attributes. Indeed, H19 upregulation was reported
in HeLa-skin fibroblast cell hybrids that became tumori-
genic following the loss of one copy of chromosome
11 [43].
Despite the above, H19 transient overexpression in
diploid cells will not necessarily prevent polyploidy. In
P53 WT hepatocellular carcinoma (HCC) cells, miR-675
transient overexpression actually increased the rate of
tetraploid cells in culture [44]. However H19 and its de-
rived miR-675 can down-regulate P53 activity, and this
temporary P53-deficiency-related stress may be the
cause of polyploidy, in accordance with the mechanism
suggested above.
The mutually exclusive nature of polyploidy and H19
expression may also be inferred by the various reported
effects of the natural drug curcumin. Curcumin treatment
of various tumor cell types resulted in H19 suppression
[45]. As curcumin induces mitotic abnormalities and sub-
sequent cytokinesis failure that are usually the basis of
polyploidy [46], the suppression of H19 by curcumin aligns
with the genome destabilization effects of curcumin.
It is worth mentioning here, however, that the mech-
anism by which H19 represses polyploidy is still unclear.
The PI3K/Akt signaling pathway was recently proposed
as a good candidate to connect the alternate cellular
fates of high H19 or polyploidy [47]. We have previously
shown that PI3K/Akt active signaling upregulates H19
to promote metastasis [48]. Apparently, PI3K/Akt is also
critical for the polyploidization phenomenon in the mur-
ine liver during weaning progression [49]. It is therefore
tempting to assume that the PI3K pathway is upstream
to the two alternative pathways that lead the stressed
cells in opposite directions. This suggestion is further
strengthened by the fact that P53 negatively regulates
the PI3K pathway via transcriptional activation of its piv-
otal negative regulator, PTEN (which is also a nega-
tive regulator of H19 and miR-675 [50]). Moreover,
P53 can also repress PI3K downstream effectors
(reviewed in [51]).
Another candidate upstream of H19/Polyploidy fates
fork is PARP-1 (poly ADP-ribose polymerase). PARP-1, a
DNA damage repair enzyme and a positive regulator
and stabilizer of P53 [52], was reported as a repressor of
H19 expression in ES cells [53]. But PARP-1 also pre-
vents polyploidy as was demonstrated in PARP-1 null
fibroblasts [54]. Therefore, it is also possible that im-
paired PARP-1, which is combined with, or resulting in,
P53 reduction, accounts for either H19 upregulation or
polyploidization.
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H19 and P53 at the junction of the hypoxic stress
response and proliferation
One of the fundamental hallmarks of cancer is uncon-
trolled, chronic cell proliferation. However, it is not only
an attribute of cancer but also one of the major engines
that drive carcinogenesis [55, 56]. The higher the rate of
proliferation, the greater the risk of acquiring either anti-
morphic mutations (resulting in oncogenic activity) or
amorphic mutations (in tumor suppressor genes (TSGs))
that may further promote proliferation [55]. Two major
regulators of cell proliferation and TSGs, P53 and RB,
are strongly affected by H19, which counteracts their ac-
tion. As mentioned above, P53 is an H19 suppressor.
Hypoxia is a common stress condition in tumors. In
addition to the abnormal vascularization commonly af-
fecting their essential nutrient and gas exchange [57],
the high proliferation rate of transformed cells impedes
their access to normal blood supply. Thus, it is not sur-
prising that hypoxia is a characteristic of all solid tumors
[58]. Hypoxia, especially of the acute type, also tends to
induce a more aggressive, invasive and resistant tumor
phenotype [59, 60].
We have previously shown that hypoxia or artificial-
hypoxia conditions induce H19 transcription [61] when
P53 is null or impaired [27]. Hence, under in vivo condi-
tions, p53 mutations which are pro-proliferative can eas-
ily lead to tissue hypoxic foci in which H19 expression is
subsequently induced. As we have demonstrated [27],
HIF1-α mediates H19 induction upon hypoxia when p53
is impaired, possibly due to the loss of P53 inhibitory
effect on HIF1-α. Apparently, nuclear localization of
P53, rather than its tetramerization (which is essential
for the translational activity of P53 protein), is essential
for H19 inhibition [27].
It has been shown in both liver and bladder cancer
cells, both in vitro and in vivo, that upon induction, H19
supports tumor growth by suppressing the cyclin-
dependent kinase inhibitor p57kip2 (CDKN1C) and other
putative tumor suppressor genes, while upregulating
pro-oncogenic genes (like cyclin E2 and others) [61].
H19 suppression of p57kip2 was evident also upon serum
depletion, a condition that usually induces p57kip2 medi-
ated quiescence [62]. Hence, once induced, H19 may
worsen the hypoxic stress, initiating a positive feedback
Fig. 1 H19 in genomic instability. Cells maintain their normal ploidy state depending on normal expression of P53, possibly in a Parp-1 dependent
manner. Reduction of P53 level (when Parp-1 is impaired?), leads either to polyploidy (attenuated track that prevents cancer progression) or to H19
upregulation (fast track to cancer, lower panel). PTEN > PI3K/Akt may be the basis of both routes. Since polyploidy (upper panel) is a common gateway
to chromosomal loss/aneuploidy, which is usually accompanied with deleterious, tumorigenic mutations, it may eventually re-elicit H19 expression
with its oncogenic properties
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loop that further promotes proliferation and subsequent
hypoxia. At the same time, as evident from our differen-
tial transcriptome analysis studies conducted both in
liver and bladder cancer cell lines [61, 62], H19 enhances
tumor survival under harsh conditions. H19 upregulates
transcription of angiogenic genes and thus enables blood
supply to the proliferating tumor. H19 also suppresses
apoptotic-signaling-related gene transcription (among
them DNA-damage sensitive genes, like the DDIT3 gene),
and promotes transcription of survival-related and chemo-
resistance related genes [61, 62]. By resisting apoptosis
under hypoxia, which is in itself a mutagenesis supporting
condition [34], H19 allows further accumulation of dele-
terious mutations. Cells under acute hypoxia are prone to
experience subsequent oxidative stress, caused by rapid
hypoxia/anoxia and reoxygenation transitions, due to the
abnormal vasculature in the tumor niche [63]. Intriguingly,
it was reported that H19 post-transcriptionally upregulates
Thioredoxin (Trx) protein in cancerous epithelial mam-
mary cells [64]. Trx, a component in the system controlling
the reduced intracellular redox environment and an abun-
dant anti-apoptotic protein in many cancers, provides
defense against oxidative stress [65]. Thus, it is possible
that H19 also confers resistance to oxidative stress on the
cancerous tissue. Indeed, H19 increased the promoter
activity of the survival factor NF-KB, a validated target of
Trx, as shown in luciferase assays [64].
Interestingly, another unexplored possible connection
between oxidative stress and H19 promoted proliferation
may be suggested from its proliferative effect in bladder
cancer cells that was reported to be exerted by upregula-
tion of Id2 (inhibitor of DNA binding/differentiation 2)
[66]. It was reported elsewhere that the levels of gluta-
thione, a physiological antioxidant, are positively corre-
lated with ID2 levels [67]. Hence, it seems that Id2’s
sensitivity to hypoxic stress may be circumvented by
H19 which may upregulate Id2 regardless of hypoxic
status.
In order to promote G1/S transition during the cell
cycle, H19 needs to avoid suppression by P53 but also
by Rb, another classic suppressor of G1/S transition and
subsequent proliferation. One of the key proteins sup-
pressed by Rb is E2F1, a transcription factor that binds
to and activates H19 promoter, as was shown in breast
cancer cells [68]. Since E2F1 is known as a G1/S transi-
tion promoting factor during the cell cycle, it is reason-
able to assume that H19 mediates the pro-proliferative
function of E2F1 [68]. Indeed, silencing of H19 in breast
cancer cells reduces their proliferation while H19 over-
expression accelerates cell cycle progression [68, 69].
Moreover, it was experimentally shown in breast cancer
cells that Rb indirectly suppresses H19 expression by
repressing E2F1 [68], while in colorectal cancer cells [10]
and in hepatocellular carcinoma cells [44], H19 derived
miR-675 negatively regulates Rb expression. This phe-
nomenon was verified in a transgenic mouse model of
prostate cancer (Pten and Zbtb7a double knockout mice),
in which Sox9 is upregulated and suppresses Rb via miR-
675 [50]. The above data, when integrated, suggest a feed-
back loop in which upregulated H19 further promotes
proliferation by repressing Rb [70]. This loop may be
accelerated in response to stress, since H19 is upregu-
lated following release from quiescence that was in-
duced by serum starvation, and E2F1 is a known
major player in quiescence to proliferation transition
[68]. Hence, H19 responds not only to hypoxic stress
but also to serum-depletion-induced quiescence by accel-
erating proliferation, dependent on the loss or dysfunction
of critical TSGs.
The convergence of P53 and Rb pathways to the H19
pivot (Fig. 2), together with the negative feedback
exerted by H19 on both of those two master TSGs, may
explain the gradual deterioration towards cancer, given
the loss of only one of the TSGs, in spite of the apparent
redundancy of the two pathways. Examples of this re-
dundancy are discussed in ref. [1].
H19 in epithelial to mesenchymal transition (EMT)
and its converse MET process: a matter of
circumstances?
Metastases are the major cause of cancer related death. Al-
though proliferation and metastasis are uncoupled pro-
cesses, it is plausible, at least according to the linear
progression paradigm that suggests an evolutionary pro-
gress towards metstasis, that hyper-proliferation increases
the somatic mutational rate that may promote a metastatic
transition [1, 71, 72]. But regardless of its involvement in
proliferation that may indirectly promote malignancy, re-
cent studies by us and others show that H19 promotes
tumor metastasis by direct involvement in malignant
processes. Metastasis is a multi-step process consisting of
apparently contrary sub-processes. EMT requires de-
differentiation of epithelial cells in order to enable dissem-
ination, migration through the extra cellular matrix (ECM)
and intravasation into blood vessels that will carry them to
their secondary site. Once extravased to the secondary site,
the tumor cell goes through the reverse mechanism of
mesenchymal to epithelial transition (MET) that resembles
re-differentiation, and then (even decades later, in some
cancers) proliferates and colonizes to become a secondary
tumor [72]. Controversial reports describe H19 as either a
pro-differentiation or a pro-proliferation factor; either an
EMT promoter or an MET promoter. We will discuss
these discrepancies in the context of metastasis as a whole.
H19 in EMT
We have recently shown that numerous bona-fide EMT
inducers also induce H19/miR-675 expression [48]. In
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HCC cells, TGF-β has been shown to induce H19 ex-
pression via activation of the PI3K/Akt signaling path-
way. This TGF-β dependent induction of H19 has been
recently corroborated in an experimental model of colo-
rectal cancer [18]. We have also found that H19 is
essential for upregulation of the EMT related transcrip-
tion factor Slug by TGF-β. In addition, hypoxia induces
H19 and miR-675 as well as the EMT markers Slug and
Snail in breast cancer cells. Association of drug resist-
ance with elevated levels of H19 and Slug was demon-
strated in a cisplatin resistant ovarian cancer cell line, in
which H19 upregulates, apparently indirectly, the pro-
moter activity of Slug, which upregulates H19 in a posi-
tive feedback loop. We have also shown that in a
pancreatic cancer cell line E-cadherin is totally ablated
upon H19 expression as long as H19’s miR-675 seed re-
gion is intact. This total ablation of E-cadherin was also
shown in HCC and lung carcinoma cells overexpressing
H19, together with the upregulation of the mesenchy-
mal N-cadherin [48]. Besides enabling dissemination,
E-cadherin loss is an essential step towards enabling
cells to adopt their cytoskeleton to migrational mode
[73]. Indeed, our studies suggest that H19 participates in
the invasion process of cancer cells; Forced expression of
H19 improves HCC cell invasiveness in an in vitro assay.
Hepatocyte growth factor/scatter factor (HGF/SF), a lig-
and of the tyrosine kinase c-Met receptor named after its
pro-migratory attributes, enhances H19 promoter activity
in treated cells in culture. Moreover, anchorage independ-
ent growth assays suggested that H19 is essential for
HGF/SF induced scattering morphology and colony for-
mation in soft agar [48].
There is a large amount of in vivo evidence supporting
the pro-metastatic nature of H19. Sub-colonies of a
mammary gland tumor cell line differ not only in their
ability to migrate to the lung and colonialize there, but
also by their relative H19 expression levels [48, 74]. In
an experimental mouse model of lung carcinoma metas-
tasis that was induced by intravenous injection of cells,
cells overexpressing H19 manifested improved ability to
metastasize in comparison to control cells transfected
with empty vector. Examination of lungs for microme-
tastases (that may serve as a measure of ability to
metastasize) and macrometastes (visible metastases; a
possible measure of proliferation) revealed that overex-
pression of H19 resulted in an increased number of lung
micrometastases compared to control mice. Macrome-
tastes were only seen in mice injected with cells
Fig. 2 H19 in proliferation and in response to hypoxic stress. Hypoxia induces H19 expression under hypoxic stress in p53 mutated cells, in which
HIF1α, which is essential to H19 upregulation, as well as H19 itself, are not repressed by P53. Since hypoxia is a mutagenic condition per se, it can
also induce p53 mutations and cause the H19 response. H19 promotes cell cycle progression through Rb suppression by its miR-675 or by
p57kip2 (CDKN1C) suppression or c-Myc activation
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overexpressing H19, suggesting that the pro-proliferative
attributes of H19 are also manifested at the secondary
site [48]. In light of all the above, it is not surprising that
high H19 levels are present in human biopsies of all
common metastatic sites tested in our study, regardless
of tumor primary origin [48].
Recently, and concurrently with our work, other re-
searchers have found additional key players in the EMT
process that are linked to H19, thus extending the net-
work of routes through which H19 exerts its metastatic
function. In bladder cancer cells, H19 was found both in
vitro and in vivo to promote EMT, down-regulation of
E-cadherin and cell migration. By association with enhan-
cer of zeste homolog 2 (EZH2), a well-established medi-
ator of tumor metastasis [75], H19 upregulates Wnt/β-
catenin signaling, which in turn represses E-cadherin
expression [20].
H19 can also promote metastasis through sponging
and sequestering of the first identified micro-RNA, let-7
[16]. This let-7-sponging function of H19, which is
conserved in both human and mouse, does not affect
let-7 RNA levels but does affect its function as a sup-
pressor of differentiation-suppressing-genes in muscle
cells (such as Hmga2 and DICER). Hence, H19 may
actually serve as a differentiation suppressor [16]. In ac-
cordance with its negative role in muscle differentiation,
it was recently reported that H19 may act as a scaffold
that favors KSRP-mediated degradation of myogenin
transcript to subsequently contribute to the maintenance
of the undifferentiated state of C2C12 muscle cells [23].
Given the differentiation suppressive attributes of H19
in muscle, it is not surprising that in pancreatic ductal
adenocarcinoma, as well as in ovarian cancer and uterine
serous carcinoma cell lines, sequestering of let-7 by H19
is essential for H19 function in EMT processes, includ-
ing cell invasion and migration [76, 77]. In ovarian can-
cer and uterine serous carcinoma cell lines, the pro
metastatic oncogene c-Myc [78, 79], which upregulates
H19 [80], is also its indirect target, due to removal of
c-Myc let-7-mediated repression. The anti-diabetic
drug Metformin can vitiate the metastatic phenotype
of ovarian cancer cell lines, apparently due to induction of
hypermethylation at the H19 locus [77]. In this context it
is highly intriguing to note that the H19/let-7 axis plays
another role in muscle: while let-7 inhibits glucose uptake
and promotes glucose intolerance, H19 upregulates insu-
lin receptor in diabetic conditions to increase glucose
uptake and is downregulated upon hyperinsulinemia [81].
Exactly how Metformin’s negative effect on H19 aligns
with its function in increasing glucose uptake in skeletal
muscle [82] (a function which is also attributed to H19)
remains to be explored. Nevertheless, let-7 is not only se-
questered by H19, but also can destabilize it under hyper-
insulinemia conditions (as opposed to the highly stabile
status of H19 in normal differentiated muscle [83]); there-
fore it exerts a negative feedback cycle to repress its nega-
tive regulator H19 [81].
A recent study contradicts the above findings since it
reported pro-differentiation properties of H19 and its
derived miR-675 forms in muscle [7]. Descriptive evi-
dence indicates that miR-675 is upregulated gradually
upon murine skeletal muscle injury in vivo to mediate
muscle regeneration and differentiation through inhib-
ition of the BMP-pathway components. This study how-
ever found that let-7 was not induced in their cell
culture model during differentiation, even though the
same muscle cell line was used. Thus, it is possible that
H19 may be capable of totally opposite functions, with
the specific functions being largely dependent on cellular
context and partners. We will come back to this point
below.
The most important lesson that can be learnt from the
H19/let7 axis findings is that positive correlation be-
tween a specific factor and a phenotype may suggest the
opposite to what one would assume. Instead of being a
differentiation factor in muscle cells, as has been
thought till recently, H19 is upregulated during myo-
differentiation mainly in order to counteract the pro-
differentiation functions of let-7 [16]. As H19 harbors
not only let-7 binding sites (both canonical and non-
canonical), but also other putative miRNA binding sites
[16], it is plausible that other miRNA interplay with
H19 in various ways. Indeed, it was recently reported
that miR-106a is also sponged by H19 in both Hela
cells and myoblasts [17]. Another fascinating finding
suggests that H19 promotes EMT by sponging two
EMT repressors, miR-134 and miR-200 in colorectal
cancer metastasis [18]. It would seem that the finding
of differentiation-correlated expression of H19 in hu-
man BM MSC [84], for example, should prompt us to
search for possible H19 targets/partners such as let-7
or miR-106a.
Another characteristic of an EMT process is the stem-
ness phenotype of the transformed cells. The stem cell-
like state of cells during EMT enables them to self-
renew and proliferate while transforming, disseminating
and migrating [85]. Interestingly, H19 maternal expres-
sion which directly impacts upregulation of Igf2 and
Igf1r, together with the repressive effect of miR-675 on
Igf1r [5], may take part in the maintenance of adult
haematopoietic stem cell quiescence [86]. Furthermore,
a recent study of prostate and breast human cell lines
revealed a putative role of stemness for H19, since its
expression was positively correlated with stem cells
markers and pluripotency factors. H19 was also found to
control the expression of two major pluripotency factors,
Oct4 and Sox2, which apparently regulate H19 in an
amplification feedback loop [87].
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H19 may act differentially depending on
developmental stage
In spite of the strong supportive evidence for H19 and
miR-675 involvement in EMT, which is regarded as a
de-differentiation/trans-differentiation process, there is
enough contradictory data to position H19 as a tumor
suppressor and a pro-differentiation factor. However,
when the data are carefully examined, it would seem
that most of the controversy may be solved by dividing
the functions of H19 into two developmental periods.
We propose that in the embryonic period H19 mostly
promotes differentiation, while in the adult it is rarely
expressed in noncancerous tissues and has tumorigenic
properties. Moreover, nullification of H19 or severely
abrogating its function in cells at early developmental
stages may impact its function at later stages, making
the cells more liable to tumorigenesis. The significance
of the embryonic expression of H19 for later stages is
implied as H19 expression in embryonic samples con-
trols the gene expression of several imprinted genes of
the imprinted gene network (IGN) by facilitating depos-
ition of repressive histone marks on their differentially
methylated regions [88], mostly by recruiting MBD1
protein to their loci [19]. Regardless of the different na-
ture of the genes H19 controls by this mechanism (for
example: the cancer related Igf2 on one hand and cell
cycle inhibitor Cdkn1c and Igf2r growth repressor on
the other), the model used to show H19 control over the
IGN was based on H19 KO (knockout) mice manifesting
an overgrowth phenotype and subsequent mating of
H19 transgenic with the KO mice to rescue the pheno-
type [88]. Assuming that the embryonic stage of H19 ex-
pression is a critical stage that impacts a set of other
imprinted genes, it is not impossible that conditional si-
lencing of the H19 in the adult would not have rescued
the overgrowth phenotype, or that conditional expres-
sion of H19 in the adult would not have achieved the
phenotypic rescue reported. According to our hypothesis,
in the second scenario, induction of H19 at later stages
may even worsen the tumorigenic phenotype. This sug-
gested distinction between embryo and adult was previ-
ously implied by Gabory and colleagues, who studied the
H19 KO mouse model described above [89].
In support of our suggestion, H19 expression leads to
growth retardation, abrogation of clonogenicity and im-
paired in vivo tumorigenesis, but these findings were
manifested in embryonic tumor cell lines [90]. Another
comprehensive study in murine KO models isolated the
H19 deletion effect from the effect of Igf2 overexpres-
sion, which commonly accompanies H19 deletion, and
showed in several tumor models that H19 has tumor
suppressing properties [91]. However the researchers
that used this murine model also disregarded possible
potential implications of lack of H19 expression during
embryonic stages. Moreover, they used ES cells in one of
their models. The researchers also admit that H19 KO
mice do not tend to spontaneously develop tumors,
which indicates that H19 is not a tumor suppressor per
se but rather its deletion increases cells tendency for
cancer. We suggest that this deletion is critical at the
embryonic stage and can also impact later stages.
The emerging role of H19 in MET
As we have seen above, H19 plays a role in EMT. Can it
also play a role in MET? Is MET, in its literal meaning
of re-differentiation, needed for metastasis at all where
H19 participates? Metastasis can be explained as a result
of either MET, the process of re-differentiation after
intravasation of the tumor cell to its secondary site, or
plasticity and stemness of the metastatic cells [85]. Plas-
ticity does not require continuous genetic alterations,
except for initiator mutations. Instead, cells adopt semi-
stemness and primitive differentiation attributes that
confer on them the ability to accommodate and react to
environmental cues, while keeping their high prolifer-
ative potential. Plasticity may be supported by revers-
ible epigenetic patterns but other mechanisms are also
possible.
We previously mentioned that H19 is highly abundant
in secondary tumors and in cell lines that complete their
journey to the secondary site. We have reported that
miR-675 is essential for EMT, ablation of epithelial
markers and upregulation of mesenchymal markers as
found in hepatocellular carcinoma in vitro. An appar-
ently conflicting report indicated that miR-675, in an-
other hepatocellular carcinoma cell line model, is an
MET promoter [44]. While increasing proliferation and
repressing Rb, miR-675 altered cellular morphology,
upregulated epithelial markers and downregulated the
mesenchymal ones, reduced invasive potential, and in-
creased anchorage-independent growth capacity. In
addition, it downregulated the EMT key mediator, Twist1
(as opposed to its high positive correlation with H19 in
the murine metastasis model of 4 T1 breast cancer cell
line in which Twist was initially identified as a metastasis
marker [74]). In prostate cancer cells, miR-675 was also
reported to suppress the extra cellular matrix TGF-β
induced (TGFBI) protein transcript, which enhances mo-
tility and invasion in metastasis. [13]. Those findings also
align with the study that claimed a pro-differentiation role
for miR-675 in muscle, as mentioned above [7].
“Selfish” H19 promotes metastasis along its
seemingly contradicting stages
We believe that the plasticity and stemness model we
described above may resolve the problems raised by the
contradictory functions attributed to H19 (Fig. 3). This
model also takes into account the key players in two
Raveh et al. Molecular Cancer  (2015) 14:184 Page 8 of 14
known pivotal negative feedback loops related to EMT-
MET balance: the ZEB1 - miR-200 loop and the Snail –
miR-34 loop [85]. ZEB1 and Snail induce EMT, growth
arrest, drug resistance and stemness in response to
TGF-β, hypoxia, chemotherapy and other inducers. In
fact, H19 shares the same inducers and effectors of EMT
as ZEB1 and Snail, as detailed above. However, ZEB1
and Snail are negatively counter-regulated at the tran-
scriptional level by miR200 and miR34, respectively.
These miRs are in turn downregulated by their target
Snail [92]. MiR-200 and miR-34 drive MET, differenti-
ation, proliferation and drug sensitivity. These feedback
loops are a mechanistic solution that provides a balance
between the two opposite processes. Interestingly, H19
was shown to suppress EMT through upregulation of
miR-200 family members by interaction with protein
complexes that induce histone acetylation upstream to
several miR200 genes. Subsequently, miR-200 mediates
H19 dependent down-regulation of Snail and Twist [93].
Furthermore, the murine 4 T1 cell line mentioned
above, the only breast cancer cell line among four clones
that completes a breast to lung metastasis, was also
the only one to express high miR-200 and H19 levels
[48, 74, 94].
Another fascinating regulatory level lies in the inhibi-
tory circuit between Snail, the repressor of miR-34 and
miR-200, and HNF4α, which, contrary to Snail, pro-
motes differentiation [92, 95]. HNF4α is a transcription
factor which is abundant in both hepatoblasts (the liver
bipotential cells that during development progressively
differentiate into hepatocytes and cholangiocytes), and in
the differentiated hepatocytes. However, it turns out that
the distinct functions of HNF4α at different develop-
mental stages of liver cells, from embryo to adult, are
due to the developmentally dependent binding pattern
of HNF4α to differential enhancers. Intriguingly, one of
Fig. 3 H19 in metastasis. H19 plays a role in both epithelial to mesenchymal transition in the primary tumor and colonization and re-
differentiation/accommodation to niche in the secondary site. As delineated above, various contradictory pathways are controlled by H19 in the
two scenarios. H19 is consolidated into the process active at that time, which is a function of the micro-environmental factors, and may find other
partners in each of the scenarios (miR-200 and let-7 in EMT and putative alternative partners such as histone acetylases in MET)
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the HNF4α enriched enhancers in embryonic liver be-
longs to the H19 gene. Moreover, it was shown that the
transcriptional co-regulator Yap1, which is the nuclear
effector of the Hippo signaling pathway, induces the
binding of HNF4α to H19 enhancer and upregulates its
expression in the embryonic liver via activation of the
transcription factor TEAD, a classical cofactor of Yap1
[96]. Yap1 promotes metastasis via TEAD [97], and was
recently found to upregulate H19 in osteosarcoma in
response to Hedgehog signaling activation [98].
In light of the above, we suggest that H19 may support
both EMT and MET (Fig. 3), conferring the cell the plas-
ticity needed throughout the stages of transformation.
H19 plays a role in EMT that eventually consolidates
with that of ZEB1 in EMT, due to their shared extracel-
lular EMT inducers. Moreover, EMT inducers such as
TGF-β also have a negative impact on miR-200 expres-
sion [99, 100], an impact that is further supported by
H19’s direct sponging of miR-200. H19 also induces
Snail expression as we have previously reported. How-
ever, in regard to the ZEB1–miR200 loop, H19 rather
promotes the MET axis, apparently by interaction with a
ribonucleoprotein complex that activates miR200 expres-
sion [93]. This interaction may explain why in MET, H19
serves rather as an inducer of miR-200 than as its spon-
ging repressor [18]. Hence, upon reduction or removal of
EMT extracellular inducers like TGF-β, or activation of
Hedgehog signaling (an established Yap1 activator [98,
101]) or, possibly, inactivation of hippo signaling (which
represses Yap1 activation), H19 shifts the cell to an “MET”
state. This shift may be further supported by upregulation
of ribonucleoprotein complexes, such as histone acetylases
[93, 102], that compete for H19 binding to exert an
MET-like phenotype.
It is also possible that H19 expression is alternatively
induced by the converse transcription factors Snail and
HNF4α in each of the opposite scenarios of EMT and
MET. These two factors may not only suppress each
other but also compete on binding to the H19 enhancer,
though this suggestion should be further explored.
Of note, P53 is a known inducer of both miR-200 and
miR-34 and hence supports MET (revieved in [85]).
Nevertheless, we have pointed out above that P53 and
H19 are, in general, mutually regulated. It is therefore
appealing to suggest that H19 is an alternative, P53
independent MET promoter, which is more favorable to
continuous cancer progression than to metastasis arrest
given its contribution to both MET and EMT.
Other transcripts on the H19 locus
As we have reviewed extensively elsewhere [3], two
major antisense transcripts reside on H19’s opposite
strand; the 120 kb-long 91H transcript and the
smaller ~6 kb HOTS transcript. The unstable 91H
[103], as opposed to H19, is exclusively nuclear, however
it shares some of H19 attributes. It is also induced during
myoblasts differentiation and upregulated in cancer (due
to RNA stabilization), as was shown in breast cancer cell
lines. However its silencing, though it has negligible effect
on H19 expression, reduces the expression of its recipro-
cally imprinted gene, Igf2, in contrary to H19’s suppressive
effect on Igf2 expression [104]. The HOTS transcript
[105] encodes for nuclear protein in primates but lacks an
open reading frame in mouse. It is still unclear whether it
is an autonomous transcript or a part of 91H. The last op-
tion is less trivial, since, according to in vitro data, HOTS
functions as a tumor-suppressor. Although loss of IGF2
imprinting leads to silencing of both H19 and HOTS, the
expression of H19 and HOTS seems to be uncoordinated,
as it is not mutually correlated across tissues. Moreover-
expression in vitro of each does not affect significantly the
expression of the other. Although the scanty data available
as for the two H19 antisense transcripts is not concrete
enough to conclude what their effect on H19’s role in
tumorigenesis might be, and in spite of the mutually
independent regulation between them and H19, they
may counteract H19 function. A possible balance be-
tween H19 and its antisense transcripts may serve as
an additional regulatory level that may dictate cellular
fate.
Conclusion
This review has taken us on a journey along the main
stations of tumorigenesis, spotlighting H19. We have
found that H19 responds to various stress conditions
such as reduced P53 and hypoxia, by activation of a
tumorigenic, selfish program of cell survival. H19 opposes
polyploidy-mediated growth arrest. Subsequent hyper-
proliferation naturally increases acquisition of further
mutations in TSGs and oncogenes that unleash tumor
progression. Following proliferation and expansion, hyp-
oxia and other triggers induce EMT, cell invasion and
extravasation. Due to possible extracellular signaling shift
in the secondary site to which the tumor cell has intrava-
sated, H19 may support MET, colonization and prolifera-
tion, processes in which H19 was already involved at the
very initial stages of tumor formation at the primary site
(illustrated in Fig. 4).
We have also highlighted the importance of H19 dur-
ing embryonic stages, proposing that at embryonic
stages H19 acts mostly as a differentiation promoter. We
have proposed that those stages may be vital for shaping
H19’s role and functions throughout development and
may impact its seemingly opposite tumorigenic roles in
the adult.
Some of the suggestions and hypotheses raised here
should be further examined and explored deeply. Al-
though we have used as holistic an approach as we could,
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we are aware of the differences between models and con-
ditions that were used in the reports we reviewed. Indeed,
to establish our proposed paradigm of H19’s involvement
throughout tumor progression from its initiative events of
translational deregulation and genomic instability to
metastasis and secondary colonization, H19 should be
studied in one, holistic, induced metastasis model
throughout cancer progression. In addition, a correl-
ation should be determined between the apparent
functions of H19, which is accompanied by a pheno-
typic output in the certain cell line of interest, and
the dynamic levels of the major players in the EMT–MET
switch this cell line expresses. Nevertheless, there is no
doubt that H19 is tightly linked to tumorigenesis
throughout all its stages. In view of its deep involve-
ment in cancer, H19 should be placed in the center of
the combat against cancer as a main therapeutic target
and a cancer marker.
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Fig. 4 Outlines for H19 functions during tumor progression. Various stress conditions drive genomic instability in its wide meaning of mutation
and chromosomal abnormalities. In some cases, such as severe reduction in P53 levels, H19 upregulation in sub-clones of stressed cells is a direct
cancerous reaction to stress that drives proliferation and accelerates mutational rate. H19 acts to enable a selfish cellular survival plan and reacts
to stress conditions by accelerating proliferation rate. H19 subsequently promotes the metastatic cascade from EMT in the primary tumor to
metastasizing in secondary sites, depending on extracellular and intercellular context
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